🇺🇸 FDA
Pipeline program

A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes

NN9733-8133

Phase 1 other active

Quick answer

A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes for Healthy Participants and Participants with type 2 diabetes is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Healthy Participants and Participants with type 2 diabetes
Phase
Phase 1
Modality
other
Status
active

Clinical trials